Fig. 1

Fingolimod treatment ameliorates RREAE but not SPEAE. a Clinical scores, and percent body weights relative to Day -1 (relative body weight, RBW), of Biozzi mice during RREAE. Mice were treated beginning on the 2nd day of disease for each mouse (n = 11–12 mice/group) through Day 45. The study was terminated on Day 46 (arrows). RBW areas under the curves were compared during the relapse period (Day 27 through 46). c Clinical scores, and percent body weights relative to Day 0 of Biozzi mice during SPEAE. Mice were treated beginning on Day 49 (dotted line) through Day 83 (n = 15–16 mice/group). The study was terminated on Day 84 (arrows). The gray area represents the efficacy period of treatment (period starting 15 days after treatment onset, i.e., Day 64, through study termination), during which clinical scores and RBW areas under the curves were compared. e Clinical scores, and percent body weights relative to Day 0 of SJL/J mice during late RREAE. Mice were treated beginning on Day 44 (dotted line) through Day 74 (n = 15 mice/group). The study was terminated on Day 75 (arrows). The gray area represents the efficacy period of treatment (Day 59 through study termination), during which clinical scores and RBW areas under the curves were compared. b, d, f Maximum EAE scores during the relapse period (b) or efficacy period of treatment (d, f). Data in a, c, and e are shown as mean + SEM and data in b, d, and f are shown as mean ± SEM. Significance was tested using an unpaired two-tailed t test (RBW area under the curve and relative end body weight) or two-tailed Mann–Whitney test (end score and maximum score). Results in c and d are representative of two independent experiments. ***p < 0.001, *p < 0.05, n.s. = not significant